Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Polymorphism Clear all
Completed No phase listed Observational

Genetics of Hepatitis C Virus Infection

NCT00005657
View directory record Official record
Conditions
Hepatitis C, Liver Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Satraplatin and Prednisone to Treat Prostate Cancer

NCT00634647
View directory record Official record
Conditions
Prostate Cancer, Genetic Polymorphism
Interventions
Satraplatin, prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 3 Interventional

Predicting the Response to Montelukast by Genetic Variation in Asthmatics

NCT00116324
View directory record Official record
Conditions
Asthma
Interventions
Montelukast
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 5, 2026, 9:15 AM EDT
Terminated Phase 4 Interventional Results available

Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

NCT00925119
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Atenolol
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study

NCT00342433
View directory record Official record
Conditions
Prostate
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
6
States / cities
San Francisco, California • Washington D.C., District of Columbia • Lanham, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

The Role of Bacteria and Genetic Variations in Cystic Fibrosis

NCT00043225
View directory record Official record
Conditions
Psuedomas Infection, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
4
States / cities
Bethesda, Maryland • Seattle, Washington • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

Genetics of Hypertension Associated Treatments (GenHAT)

NCT00006294
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions
Chlorthalidone, Lisinopril, Amlodipine, Doxazosin
Drug
Lead sponsor
Donna Arnett, 257-5678
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting No phase listed Observational

Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke

NCT06292117
View directory record Official record
Conditions
Ischemic Stroke, CYP2C19 Polymorphism
Interventions
CYP2C19 Genotype
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Risk Evaluation and Education for Alzheimer's Disease

NCT00571025
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
APOE Disclosure
Behavioral
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting No phase listed Observational

Genetic Markers of Cardiovascular Disease in Epilepsy

NCT02824822
View directory record Official record
Conditions
Epilepsy, Seizures, Syncope, Channelopathy, Cardiomyopathies
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Beta-2 Polymorphisms and Beta Receptor Selectivity

NCT00214318
View directory record Official record
Conditions
Heart Failure
Interventions
Terbutaline plus Metoprolol or carvedilol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

B2-Adrenergic Receptor Polymorphisms

NCT00279786
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Blood draw
Procedure
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
2 Years to 18 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

NCT02900976
View directory record Official record
Conditions
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Withdrawn No phase listed Observational

Pharmacogenomics in Pulmonary Arterial Hypertension

NCT00593905
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions
Sitaxsentan, Bosentan, Ambrisentan
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 5, 2026, 9:15 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 5, 2026, 9:15 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

NCT01447199
View directory record Official record
Conditions
Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Skin Cancer, Uterus Cancer
Interventions
Health and Diet Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

International Guillain-Barré Syndrome Outcome Study

NCT01582763
View directory record Official record
Conditions
Guillain-Barré Syndrome, Miller Fisher Syndrome
Interventions
Not listed
Lead sponsor
Erasmus Medical Center
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 5, 2026, 9:15 AM EDT
Withdrawn Phase 2 Interventional

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

NCT04138875
View directory record Official record
Conditions
PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
Interventions
Rituximab, Brentuximab Vedotin, Bendamustine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia

NCT00897507
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Sep 5, 2026, 9:15 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

NCT07145333
View directory record Official record
Conditions
SCLC
Interventions
Topotecan - usual, Topotecan - study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Not applicable Interventional

Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM

NCT02428660
View directory record Official record
Conditions
Cytochrome P450 CYP2D6 Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Ultrarapid Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Extensive Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, CYP2D6 Polymorphism
Interventions
Pharmacogenetic testing, Software-based drug & gene interaction risk analysis, MTM
Genetic · Other
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 5, 2026, 9:15 AM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

NCT02065479
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 5, 2026, 9:15 AM EDT
Recruiting Phase 1 Interventional

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

NCT07148089
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
SGT-501
Drug
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
7 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 5, 2026, 9:15 AM EDT
Completed No phase listed Observational

Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C

NCT00040729
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
mutation analysis
Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 5, 2026, 9:15 AM EDT